Dimitrios Liokaftos
Microdosing consists of the regular use of sub-perceptive doses of psychedelics substances, most notably psilocybin (“magic”) mushrooms and lysergic acid diethylamide (LSD). First observed in specific environments and subcultures before spreading in wider areas of human activity, microdosing has become one of the better recognised faces of the current “psychedelics renaissance.” Building on a...
Dimitrios Liokaftos
Background: In recent years, microdosing psychedelics has been a growing phenomenon attracting media, popular and scientific attention. The practice entails the use of sub-hallucinogenic doses of psychedelics substances such as LSD and psilocybin mushrooms. Users report a multiplicity of motivations for and benefits from engaging with microdosing that run across the enhancement/therapy...
Vincent Wesley Couey
QSAR models for hERG cardiotoxicity are increasingly deployed in pre‑IND cardiac safety triage of psychedelic‑class therapeutics under accelerated regulatory review. We make two contributions. Empirical: across three structurally independent psychedelic compound families (22 tryptamines, 20 phenethylamines, 17 cathinones; 59 compounds spanning natural products to FDA‑approved medications),...
Alexander J. Bradshaw, Cathy Sharp, Breyten Van der Merwe et al.
preprint
Abstract The “magic mushroom” Psilocybe cubensis is cultivated worldwide for recreational and medicinal uses. Described initially from Cuba in 1904, there has been substantial debate about its origin and diversification. The prevailing view, first proposed by the Psilocybe expert Gastón Guzmán in 1983, is that P. cubensis was inadvertently introduced to the Americas when cattle were introduced...
Aaron Roberts
preprint
The public perception of psychedelic substances has become considerably more favorable in recent years. This shift can be seen in decriminalization measures passed in several U.S. cities as well as Oregon’s commitment to establish a state-licensed psilocybin-assisted psychotherapy program. These dramatic developments beg the question: Why now? Three particular aspects of psychedelic drugs have...
Michael Alvear
preprint
Patients undergoing ketamine-or psychedelic-assisted therapy for cancer-related distress, treatment-resistant depression, or end-of-life existential fear frequently report experiences resembling death or near-death: a sense of leaving the body, encountering something transcendent, or having died and returned. This synthesis reviews peer-reviewed evidence on how often this occurs, why it may...
Vincent Joralemon
preprint
Psychedelic therapies—ketamine, MDMA, psilocybin, LSD, DMT, and ibogaine—are moving from prohibition to regulated care, but commercialization hinges on FDA approval, DEA scheduling, and payor (insurance) coverage. This Article maps the U.S. regulatory labyrinth and analyzes how business models succeed or fail under these constraints. It explains bifurcated rescheduling (DEA reschedules the...
Vincent Joralemon
preprint
Clinical trials for novel therapeutics are extraordinarily expensive, and psychedelicassisted therapies pose a particular financing challenge: the underlying compounds (MDMA, psilocybin, LSD, ibogaine) are off-patent or unpatentable, limiting the traditional commercial incentives that fund late-stage drug development. This essay examines an emerging alternative-the "pseudo-nonprofit" financing...
Dustin Marlan
preprint
The law has long protected movement through physical space. This Article asks whether it should also protect movement through mental space. Psychedelics are reemerging in law and culture after decades of prohibition, but the prevailing justifications for reform--medical utility, religious freedom, neurodiversity, free speech, and especially cognitive liberty--either protect too few or fail to...
Matthias Forstmann, Christina Sagioglou
preprint
After decades of stagnancy, research on psychedelic substances (such as LSD, psilocybin or DMT) has experienced a renaissance over the last 10 years, with various major research programs being conducted across Europe and the United States. This research primarily investigates the potential of psychedelics in the treatment of mental health disorders, their short and long term effects on...